Participants were excluded if they used these drugs in the year before enrolment or had contraindications to them
Risk of Fracture with Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Real-World Use: Systematic Review and Meta-Analysis of Observational Studies. Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol
The FDA is also tracking some adverse event reports that starting GLP-1 treatment caused or exacerbated serious psychiatric conditions associated with depression and suicidality
Many people describe eating roughly a third of what they previously ate, not through effort but because they genuinely stop feeling hungry
The shift in gut motility, combined with changes in bile acid absorption and fluid balance in the intestines, can lead to diarrhea, particularly during dose increases
An at-a-glance look at considerations for GLP-1 timing Still not sure which is the best fit for you